merakris_logo_4color copy.jpg
Study Shows Effectiveness of Merakris’ Wound Care Products
02 juin 2022 07h30 HE | Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 02, 2022 (GLOBE NEWSWIRE) -- A peer-reviewed case study in the May 21 edition of SAGE Open Medical Case Reports highlights the effectiveness of two Merakris...
merakris_logo_4color copy.jpg
Merakris Announces Agreement With Miracles In Sight Eye Bank To Supply Opticyte® Repair Grafts to Eye Surgeons
20 juil. 2021 06h30 HE | Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 20, 2021 (GLOBE NEWSWIRE) -- Research Triangle Park-based biotechnology company Merakris Therapeutics has reached an agreement with Miracles In Sight (MIS) to...
1.jpg
BioStem Life Sciences, Inc., Subsidiary of BioStem Technologies, Inc., Announces Entry into Market with Four Amniotic Products
01 oct. 2018 10h45 HE | BioStem Technologies, Inc.
Pompano Beach, FL, Oct. 01, 2018 (GLOBE NEWSWIRE) -- BioStem Life Sciences (“Life Sciences” or the “Company”), a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM), a...
AmnioLife to Partici
AmnioLife to Participate at First Annual Interventional Orthopedic Foundation Conference October 23rd & 24th
06 oct. 2015 05h00 HE | AmnioLife Corporation
GAINESVILLE, Fla., Oct. 06, 2015 (GLOBE NEWSWIRE) -- AmnioLife Corporation, a human cells, tissues, and cellular and tissue-based products developer, today announced that its CEO and Lead Scientist...
FL-Based Biotech, Am
FL-Based Biotech, AmnioLife Corp. Closes $833K in Series A
03 juin 2015 06h30 HE | AmnioLife Corporation
GAINESVILLE, Fla., June 03, 2015 (GLOBE NEWSWIRE) -- AmnioLife Corporation, a human cells, tissues, and cellular and tissue-based products developer, today announced it has raised $833K in a Series...